Χώρα: Μάλτα
Γλώσσα: Αγγλικά
Πηγή: Medicines Authority
SALBUTAMOL
Glaxo SmithKline Ireland Limited 12, Riverwalk, Citywest Business Campus, Dublin 24, Ireland
R03AC02
SALBUTAMOL 2 mg/5ml
ORAL SOLUTION
SALBUTAMOL 2 mg/5ml
POM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Authorised
2005-09-12
1 GSK LOGO PACKAGE LEAFLET: INFORMATION FOR THE USER VENTOLIN 2 MG/5 ML ORAL SOLUTION SALBUTAMOL (AS SULFATE) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor, nurse or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet IN THIS LEAFLET: 1 What Ventolin Oral Solution is and what it is used for 2 What you need to know before you take Ventolin Oral Solution 3 How to take Ventolin Oral Solution 4 Possible side effects 5 How to store Ventolin Oral Solution 6 Contents of the pack and other information Ventolin 2 mg/5 ml Oral Solution (called ‘Ventolin Oral Solution’ in this leaflet) contains a medicine called salbutamol. This belongs to a group of medicines called fast acting bronchodilators. • Bronchodilators help the airways in your lungs to stay open. This makes it easier for air to get in and out. • They help to relieve chest tightness, wheezing and cough. Ventolin Oral Solution is used to treat breathing problems in adults, adolescents and children with asthma, bronchitis and emphysema. DO NOT TAKE VENTOLIN ORAL SOLUTION: • if you are allergic (hypersensitive) to salbutamol sulfate or any of the other ingredients of Ventolin Oral Solution (listed in Section 6). WARNINGS AND PRECAUTIONS Talk to your doctor, nurse or pharmacist before taking Ventolin Oral Solution if: • you have high blood pressure • you are diabetic • you have an overactive thyroid gland • you have a history of heart problems such as an irregular or fast heartbeat or angina • you suffer from acute severe asthma (your doctor may need to carry out blood tests to monitor the amount of potassium in yo Διαβάστε το πλήρες έγγραφο
1 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Ventolin 2mg/5ml Oral Solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 5ml of solution contains 2mg salbutamol as salbutamol sulfate. Excipient with known effect: Sodium benzoate, benzyl alcohol, propylene glycol For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Oral solution. A clear, colourless to pale straw coloured liquid. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Ventolin Oral Solution is indicated for the treatment or prevention of bronchospasm. It provides short acting bronchodilation in reversible airways obstruction due to asthma and chronic obstructive pulmonary disease (COPD) such as chronic bronchitis and emphysema. Ventolin Oral Solution is indicated in adults, adolescents and children aged 2 to 12 years. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Adults (over 18 years) _ 10 to 20 ml of Oral Solution (4 to 8 mg salbutamol) three or four times daily. _Paediatric Population _ Children aged 2 to 6 years: 2.5 to 5 ml of Oral Solution (1 to 2 mg salbutamol) three or four times daily. Children aged 6 to 12 years: 5 ml of Oral Solution (2 mg salbutamol) three or four times daily. Children aged over 12 years: 5 to 10 ml of Oral Solution (2 to 4 mg salbutamol) three or four times daily. _Special patient groups _ In elderly patients or in those known to be unusually sensitive to beta-adrenergic stimulant drugs, it is advisable to initiate treatment with 5ml of oral solution (2 milligram salbutamol) three or four times per day. 2 Method of Administration Salbutamol has a duration of action of 4 to 6 hours in most patients. Increasing use of beta-2 agonists may be a sign of worsening asthma. Under these conditions a reassessment of the patient's therapy plan may be required and concomitant glucocorticosteroid therapy should be considered. As there may be adverse effects associated with excessive dosing, the dosage or frequency of administration should only be increased on medical advice. 4.3 CON Διαβάστε το πλήρες έγγραφο